Overview
Spherix’s coverage of emerging gastroenterology indications focuses on evolving markets where a paradigm shift is expected in the coming years.
Services Available
Prepping for the pipeline
Celiac Disease (US)
Clostridioides Difficile (US)
Primary Biliary Cholangitis (US)
Eosinophilic Esophagitis (US)
Nonalcoholic Fatty Liver Disease/Non alcoholic Steatohepatitis (US)
Benchmarking new brand perfomance
APT 1011 (Ellodi) in Eosinophilic Esophagitis (US)*
Dupixent (Sanofi/Regeneron) in in Eosinophilic Esophagitis (US)*
Eohilia (Takeda) in in Eosinophilic Esophagitis (US)*
*Pending approvals and launch